Physician profile
Jia Bi
NPI 1174556492
$2,983.70
in general payments reported to CMS, 2019-2025
46 companies · $713 in 2025
The $713 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $294 · 2022: $94.63 · 2023: $346 · 2024: $400 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $486.39 | 2019-2025 | |
| Celgene Corporation | $260.83 | 2019-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $237.33 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Alexion Pharmaceuticals, INC. | $209.55 | 2019-2024 | Ultomiris |
| Abbvie INC. | $177.23 | 2022-2025 | Venclexta |
| Genentech USA, INC. | $110.30 | 2019-2025 | Tecentriq Hybreza |
| Janssen Biotech, INC. | $87.90 | 2019-2024 | Tecvayli, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $86.55 | 2019-2025 | Opdualag, Opdivo |
| Tesaro, INC. | $79.24 | 2019 | |
| Eisai INC. | $69.44 | 2019-2023 | |
| Gilead Sciences, INC. | $65.31 | 2019-2023 | |
| Puma Biotechnology, INC. | $61.79 | 2019-2025 | |
| Amgen INC. | $58.91 | 2019 | |
| Genzyme Corporation | $55.86 | 2019-2025 | |
| Incyte Corporation | $55.72 | 2019-2023 | Pemazyre, Monjuvi, Jakafi |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jia Bi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.